{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:27:04Z","timestamp":1780514824988,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40801-015-0028-3","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T08:33:33Z","timestamp":1436949213000},"page":"199-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia"],"prefix":"10.1007","volume":"2","author":[{"given":"Samantha A.","family":"Hollingworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Treasure M.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn J.","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"issue":"5","key":"28_CR1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/pds.2114","volume":"20","author":"SA Hollingworth","year":"2011","unstructured":"Hollingworth SA, Rush A, Hall WD, Eadie MJ. Utilization of anti-Parkinson drugs in Australia: 1995\u20132009. Pharmacoepidemiol Drug Saf. 2011;20(5):450\u20136.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"28_CR2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00002018-200124110-00007","volume":"24","author":"M Etminan","year":"2001","unstructured":"Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson\u2019s disease: a meta-analysis of randomised controlled trials. Drug Saf. 2001;24(11):863\u20138.","journal-title":"Drug Saf"},{"issue":"7352","key":"28_CR3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/bmj.324.7352.1483","volume":"324","author":"CN Homann","year":"2002","unstructured":"Homann CN, Wenzel K, Suppan K, Ivanic G, Kriechbaum N, Crevenna R, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ. 2002;324(7352):1483\u20137.","journal-title":"BMJ"},{"issue":"3","key":"28_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11539720-000000000-00000","volume":"25","author":"B Knie","year":"2011","unstructured":"Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson\u2019s disease. CNS Drugs. 2011;25(3):203\u201312.","journal-title":"CNS Drugs."},{"issue":"6","key":"28_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-200932060-00004","volume":"32","author":"A Antonini","year":"2009","unstructured":"Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson\u2019s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32(6):475\u201388.","journal-title":"Drug Saf"},{"issue":"5","key":"28_CR6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00023210-200822050-00004","volume":"22","author":"M Lader","year":"2008","unstructured":"Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs. 2008;22(5):407\u201316.","journal-title":"CNS Drugs."},{"issue":"12","key":"28_CR7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Internal Med. 2014;174(12):1930\u20133.","journal-title":"JAMA Internal Med."},{"issue":"1","key":"28_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. NEJM. 2007;356(1):29\u201338.","journal-title":"NEJM."},{"issue":"1","key":"28_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. NEJM. 2007;356(1):39\u201346.","journal-title":"NEJM."},{"issue":"2","key":"28_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","volume":"35","author":"G Trifiro","year":"2012","unstructured":"Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35(2):159\u201371.","journal-title":"Drug Saf"},{"key":"28_CR11","unstructured":"Adverse Drug Reactions Advisory Committee (ADRAC). Pathological gambling with cabergoline. Aust Adv Drug React Bull. 2005;24(August 2005):15."},{"key":"28_CR12","unstructured":"Adverse Drug Reactions Advisory Committee (ADRAC). Ergot derivatives and fibrotic reactions. Aust Adv Drug React Bull. 2006;25(February 2006):3."},{"key":"28_CR13","unstructured":"Food and Drug Administration. Public Health Advisory\u2014Pergolide (marketed as Permax). 2007. http:\/\/www.fdagov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm051285htm . Accessed 15 Jan 2015."},{"issue":"4","key":"28_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/11588230-000000000-00000","volume":"34","author":"N Ooba","year":"2011","unstructured":"Ooba N, Yamaguchi T, Kubota K. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug Saf. 2011;34(4):329\u201338.","journal-title":"Drug Saf"},{"key":"28_CR15","doi-asserted-by":"crossref","unstructured":"Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL, French Association of Regional Pharmacovigilance C. Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. Mov Disord. 2010;25(12):1876\u201380.","DOI":"10.1002\/mds.23204"},{"issue":"4","key":"28_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","volume":"19","author":"AH Evans","year":"2004","unstructured":"Evans AH, Katzenschlager R, Paviour D, O\u2019Sullivan JD, Appel S, Lawrence AD, et al. Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19(4):397\u2013405.","journal-title":"Mov Disord."},{"issue":"12","key":"28_CR17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/mds.20330","volume":"19","author":"KR Chaudhuri","year":"2004","unstructured":"Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord. 2004;19(12):1522\u20133.","journal-title":"Mov Disord."},{"issue":"6","key":"28_CR18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"J Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10(6):334\u20136.","journal-title":"Cardiol Rev."},{"issue":"10","key":"28_CR19","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1345\/aph.18461","volume":"33","author":"S Champagne","year":"1999","unstructured":"Champagne S, Coste E, Peyriere H, Nigond J, Mania E, Pons M, et al. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases. Ann Pharmacother. 1999;33(10):1050\u20134.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"28_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"key":"28_CR21","first-page":"12","volume":"31","author":"G Moses","year":"2005","unstructured":"Moses G, McGuire T. Consumer ADR reporting\u2014alive and well in Australia. Uppsala Rep. 2005;31:12\u20133.","journal-title":"Uppsala Rep."},{"issue":"10","key":"28_CR22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5694\/mja13.10069","volume":"199","author":"J Robertson","year":"2013","unstructured":"Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684\u20136.","journal-title":"Med J Aust."},{"key":"28_CR23","doi-asserted-by":"crossref","unstructured":"McGuire T, Moses G. Medical Mishap. \u2018Statins\u2019 and muscle symptoms. Aust Prescr. 2005;28(4):102.","DOI":"10.18773\/austprescr.2005.078"},{"issue":"3","key":"28_CR24","first-page":"99","volume":"35","author":"Medicines Safety Update","year":"2012","unstructured":"Medicines Safety Update. Zolpidem: continued reporting of abnormal sleep-related events and amnesia. Aust Prescr. 2012;35(3):99.","journal-title":"Aust Prescr."},{"issue":"1","key":"28_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1345\/aph.1C126","volume":"37","author":"H Peyriere","year":"2003","unstructured":"Peyriere H, Cassan S, Floutard E, Riviere S, Blayac JP, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacother. 2003;37(1):5\u201311.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"28_CR26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891\u20138.","journal-title":"Drug Saf"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-015-0028-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0028-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:13:28Z","timestamp":1551204808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-015-0028-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s40801-015-0028-3","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}